ACTN4 and prostate cancer: There are biomarkers in EVs that respond to the prognosis of prostate cancer, such as ACTN4 (α-coactinomycin 4), PD-L1 (programmed death receptor ligand 1), Integrin αvβ3 (Integrin αvβ3), and Del-1 (Developmental endothelial locus-1), which have been correlated with the poor prognosis of prostate cancer, therefore the prognosis of patients can be assessed by detecting EVs in serum.